Chief Executive Officer
Dr. Chang is the Chairman and CEO of OBI Pharma, and founder of both Optimer Pharmaceuticals and OBI. Dr. Chang has served as President and Chief Executive Officer at Optimer from November 1998 until May 2010. In 1994, Dr. Chang established Pharmanex, a health products company, which was acquired by NuSkin Enterprises, where he was appointed Chief Scientific Adviser. Prior to this, he founded Cinogen in 1993. Dr. Chang was formerly the Director of Medical Chemistry at Rhone-Poulenc Rorer and Deputy Director of Medicinal Chemistry at Merck, Sharpe & Dohme (US Merck). Dr. Chang received his Ph.D. in Organic Chemistry from Brandeis University, and conducted postdoctoral research at Massachusetts Institute of Technology (MIT). He received his BS in Chemistry from Fu Jen Catholic University in Taiwan. He holds 39 patents and has published more than 69 scientific papers in peer reviewed journals.
Chief Scientific Officer
Dr. Lai has more than 23 years of experience in drug discovery. As Senior Principal Scientist at Merck & Co., Dr. Lai led and directed multiple independent project teams to develop potential clinical candidates. He also acted as a core team member of early development and product development in several clinical studies. During his tenure at Merck, the teams have identified more than 10 preclinical candidates. Several of them are currently in clinical trials. He also received several awards from Merck, Merck Divisional/Staff Area Award in 2007, Special achievement award in 2009, and Merck Research Laboratories Pipeline Award in 2018. The crowing achievements of his career at Merck comes with the approval of an antiviral drug by FDA in 2018. Dr. Lai has had over 69 papers published in peer-reviewed journals. Dr. Lai did post-doctoral study in at Massachusetts Institute of Technology, earned his Ph.D. in Bio-Organic Chemistry from University of Minnesota.
Chief Medical Officer
Dr. Pearce has served as OBI Pharma’s Medical Advisor since 2017. He has over twenty-seven years of international experience in both large pharma and small biotech, including development of therapeutics in the areas of solid tumors, hematologic malignancies, immuno-oncology, inflammation and infectious diseases. Prior to working with OBI, Dr. Pearce held several senior executive roles including as CMO at Threshold Pharmaceuticals, and at KaloBios Pharmaceuticals. Dr. Pearce also has extensive pharma experience in Europe, including as Senior Director of Clinical Research at PDL Pharma, as Medical Director of the Oncology Business Unit at Sanofi-Synthelabo, S.A. in Paris, France, and as Director of Clinical Research in oncology at Novartis Pharma AG in Basle, Switzerland.
Chief Financial Officer
Mr. Chen is currently serving as Vice General Manager, Investment Management and Special Assistant to Chairman of Ruentex Group. He obtained his master’s degree in Business Administration from National Taiwan University.
Chief Operating Officer (USA)
Mitch Che joins OBI Pharma USA Inc. as Chief Operating Officer where he brings over twenty years’ operational and technical expertise spanning the pharmaceutical, telecom, and transportation and logistics industries. Prior to joining OBI Pharma USA Inc., Mitch was Vice President of Facilities, Operations and Procurement for Optimer Pharmaceuticals. Previously, Mitch held positions at AT&T and BP, as well as managing his own executive consulting firm. He is responsible for the development and management of OBI Pharma USA’s operating plans, results, strategic US operations and global IT supporting R&D, clinical and business development plans. Mitch has a B.S. degree in Geochemistry from Brown University and an M.S. degree from the University of California, Berkeley.
Kevin P Poulos
Chief Commercial Officer (USA)
Kevin has over twenty years of senior management experience in various strategic commercial and business development functions both internationally and the United States with Optimer, Wyeth, Rhone-Poulenc Rorer and SmithKline Beecham. Prior to joining OBI Pharma, Inc., he was the President of KPP Biopharmaceutical Commercial Consulting and the Chief Commercial Officer at Optimer Pharmaceuticals. During his career, Kevin oversaw the international and US commercial launches of many innovative pharmaceutical products including Dificid®, Zyvox®, Synercid®, Zagam®, Zosyn®/Tazocin® and Timentin®. He received his B.S. degree in Business Administration from Old Dominion University.
Global RA VP (USA)
Dr. Hallinan has over 25 years of operational and regulatory affairs experience across a range of therapeutic areas. Prior to joining OBI, David was VP Regulatory Affairs at Idenix Pharmaceuticals, and VP Regulatory Affairs and Quality Assurance at Parexel International. He holds a Ph.D. in Pharmacology and a B.S. in Biochemistry from University College, Dublin, Ireland.
Chief Executive Officer (Shanghai)
Ms. Huang joins OBI, Inc. after a distinguished career at GlaxoSmithKline, where she was Vice President and Regional Director responsible for all commercial operations in China and Hong Kong. Ms. Huang is an inspirational leader and successful executive with numerous awards and achievements, including Outstanding Pharmaceutical Manager (Taiwan) and GSK´s Inspirational Leadership Award (2005).
Since the merger of Glaxo Wellcome and SmithKline Beecham in 2001, she presided over record country performances during a turbulent period of regulation in Taiwan’s pharmaceutical industry. During her tenure as Managing Director of SmithKline Beecham Taiwan, she oversaw the launches of novel products, such as Engerix B, Tagamet, Augmentin, Avandia, and Seretide, representing some of the most successful.
Cheng-Der (Tony) Yu
Chief Scientific Advisor
Dr. Yu is a pharmaceutical scientist with over 35 years of R&D and general management experience in the pharmaceutical industry. Prior to joining OBI, Dr. Yu was the General Manager and Chief Scientific Officer at Microbio, Inc. He was Senior VP at the University Pharmaceuticals of Maryland. During his 14-year tenure at Bristol-Myers Squibb, which preceded his career at UPM, he participated in numerous IND and NDA filings, as well as numerous product launches. He holds 7 patents in the areas of drug delivery and product stability and has published over 35 peer reviewed scientific papers and book chapters. He was a recipient of the American Pharmaceutical Association’s Ebert Prize Award, shortly after he finished his Ph.D. in Pharmaceutics from the University of Michigan. Dr. Yu earned a Pharm.D. from the University of Florida and holds a B.S. degree in Pharmacy from National Taiwan University.